---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001872"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:39:58.163619+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics Chief R&D Strategy Officer David Liu transitions to part-time advisor due to health reasons

## Summary
- David Liu stepped down as Chief R&D Strategy Officer effective Jan 1, 2023, due to health reasons.
- He will continue as a part-time R&D Strategy Advisor, no longer an executive officer.
- No replacement named for the role of Chief R&D Strategy Officer.
- Liu is no longer a Section 16 officer, reducing executive team.

## SEC filing metadata
- accession: 0001104659-23-001872
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/0001104659-23-001872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/tm232306d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001872
- JSON: https://secwatch.observer/filing/0001104659-23-001872.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001872.txt

## Key facts
- Executive change
  David Liu changed role as Chief R&D Strategy Officer at Protagonist Therapeutics, Inc.
  - Action: transitioned to a part-time R&D Strategy Advisor
  - Role: Chief R&D Strategy Officer
  source text: Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.’s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/0001104659-23-001872-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.